The GLP-1 Tipping Point: A Structural Shift in Consumption π¨
Occasionally, an innovation comes along that fundamentally rewires consumer behavior. The rapid adoption of GLP-1 receptor agonists β drugs like Novo Nordisk's Wegovy and Eli Lilly's Zepbound β is doing exactly that. According to Gallup, 11% of U.S. adults are now using these injectables for weight loss, nearly quadrupling from just 3% two years ago. π
J.P. Morgan Global Research forecasts that 25 million Americans will be on GLP-1 treatment by 2030, up from roughly 10 million last year. The implications stretch far beyond healthcare β this is a tectonic shift in the $1.8 trillion food and beverage economy.
Key Insight: The adult obesity rate in the U.S. has already fallen from 39.9% in 2022 to 36.8% in 2026. This isn't a fad β it's a structural repricing of calorie consumption.
Winners and Losers: Who Collects, Who Pays? βοΈ
π The Collectors: Big Pharma's Dominance
Eli Lilly (NYSE: LLY) is the undisputed king. Its tirzepatide franchise (Mounjaro + Zepbound) generated $36.5 billion in combined 2025 sales, making it the world's best-selling drug. LLY shares have climbed over 400% in five years, with a market cap of $1.1 trillion and a stellar 83.4% gross margin.
Novo Nordisk (NVO) isn't far behind. Wegovy and Ozempic pulled in $31 billion last year, making Novo Denmark's largest company β its market cap equals roughly one-third of the country's GDP. While NVO shares have lagged LLY recently, revenue more than doubled between 2021 and 2025.
π The Squeezed: Snack Makers Under Pressure
A December 2025 study in the Journal of Marketing Research found grocery spending by GLP-1 households fell 5.3% within six months, with savory snacks dropping ~10%. J.P. Morgan projects a $30Bβ$55B annual revenue hit for the food and beverage industry by 2030β2034.
- PepsiCo (NASDAQ: PEP): Down 12% YoY. Lay's is among the most exposed brands. Superscore: 71/100.
- Hershey (NYSE: HSY): Down ~17% YoY. Candy sales pressured β though breath mint demand (Ice Breakers, Breath Savers) is surging due to dry-mouth side effects.
- Mondelez (NASDAQ: MDLZ): Flat YoY. 75% of sales are international, giving it a temporary buffer.
The market is deeply divided on whether GLP-1 disruption is fully priced in. Here's how bulls and bears are framing the trade:
π Head-to-Head Comparison: GLP-1 Exposure Scorecard
| Company | Ticker | 1Y Performance | GLP-1 Exposure | Verdict |
|---|---|---|---|---|
| Eli Lilly | LLY | +400% (5Y) | π’ Direct Beneficiary | Strong Buy |
| Novo Nordisk | NVO | Negative (1Y) | π’ Direct Beneficiary | Accumulate |
| Coca-Cola | KO | +34% | π‘ Low (68% zero/low-cal) | Hold |
| Monster Beverage | MNST | +27% | π‘ Low (energy drinks resilient) | Hold |
| PepsiCo | PEP | -12% | π΄ High (snack-heavy) | Caution |
| Mondelez | MDLZ | Flat | π Medium (intl. buffer) | Neutral |
| Hershey | HSY | -17% | π΄ High (candy) | Caution |
π Technical Read
LLY's 52-week range ($783.85β$1,292.65) shows a strong uptrend with higher lows. PEP, by contrast, is grinding near 52-week lows ($123.47), with resistance forming around $140. Historically, when a consumer staple breaks below its 200-day moving average on declining snack volumes β as PEP has β the recovery tends to lag by 2β3 quarters.
π In-Depth Fundamental Analysis
| Company | Share Price | P/E Ratio | P/B Ratio | ROE | Operating Margin (OPM) | Revenue Growth |
|---|---|---|---|---|---|---|
| HSY (The) | $163 | 22.23 | 7.17 | 32.81% | 23.12% | 6.60% |
| KO (Coca-Cola) | $88 | 26.44 | 10.48 | 42.05% | 34.87% | 6.70% |
| LLY (Eli) | $1,179 | 39.59 | 31.03 | 102.29% | 54.22% | 47.70% |
| MDLZ (Mondelez) | $60 | 22.21 | 2.90 | 13.34% | 21.98% | 4.10% |
| MNST (Monster) | $44 | 40.41 | 9.13 | 25.70% | 29.18% | 20.20% |
| NVO (Novo) | $39 | 9.45 | 5.10 | 59.81% | 42.54% | 2.10% |
| PEP (Pepsico,) | $126 | 15.85 | 7.79 | 52.19% | 16.88% | 5.60% |
The Bottom Line: Positioning for the GLP-1 Decade π―
Best Case Scenario (Bullish): GLP-1 adoption accelerates globally, oral pills launch in 2027β2028, and pharma leaders (LLY, NVO) capture a multi-decade tailwind. Snack companies that pivot to portion-controlled, protein-rich, or low-calorie SKUs (KO, MNST) stabilize.
Worst Case Scenario (Bearish): Generic GLP-1 competition compresses drugmaker margins, while snack makers fail to adapt. PEP, HSY, and MDLZ face sustained volume declines, and the $30Bβ$55B revenue hit materializes fully by 2034.
Investor Takeaway: The GLP-1 trade isn't just a pharma story β it's a cross-sector rotation. Investors should watch for continued divergence between the collectors (LLY, NVO) and the squeezed (PEP, HSY). Diversification across resilient beverage names (KO, MNST) offers a defensive hedge. β οΈ All investing carries risk β position sizing and due diligence remain essential.
